CN103655505B - A kind of pain relieving class two-layer release-controlled tablet and preparation method thereof - Google Patents
A kind of pain relieving class two-layer release-controlled tablet and preparation method thereof Download PDFInfo
- Publication number
- CN103655505B CN103655505B CN201310716482.6A CN201310716482A CN103655505B CN 103655505 B CN103655505 B CN 103655505B CN 201310716482 A CN201310716482 A CN 201310716482A CN 103655505 B CN103655505 B CN 103655505B
- Authority
- CN
- China
- Prior art keywords
- release
- layer
- slow
- tablet
- release layer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 239000008187 granular material Substances 0.000 claims abstract description 58
- 239000003814 drug Substances 0.000 claims abstract description 37
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims abstract description 22
- 229940079593 drug Drugs 0.000 claims abstract description 19
- 230000000202 analgesic effect Effects 0.000 claims abstract description 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 12
- 239000000463 material Substances 0.000 claims abstract description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 28
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 28
- 235000019359 magnesium stearate Nutrition 0.000 claims description 14
- 239000000377 silicon dioxide Substances 0.000 claims description 14
- 235000012239 silicon dioxide Nutrition 0.000 claims description 14
- 238000000576 coating method Methods 0.000 claims description 12
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 11
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 11
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 11
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 11
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 8
- 229960001680 ibuprofen Drugs 0.000 claims description 8
- 239000008101 lactose Substances 0.000 claims description 8
- 229960001375 lactose Drugs 0.000 claims description 8
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 6
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 6
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 5
- 239000011230 binding agent Substances 0.000 claims description 5
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 5
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 4
- 239000000945 filler Substances 0.000 claims description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 4
- WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 238000004132 cross linking Methods 0.000 claims description 3
- 150000002576 ketones Chemical class 0.000 claims description 3
- 239000000314 lubricant Substances 0.000 claims description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 claims description 2
- WTQYWNWRJNXDEG-UHFFFAOYSA-N 6-Hydroxy-hyoscyamin Natural products CN1C(C2)CC(O)C1CC2OC(=O)C(CO)C1=CC=CC=C1 WTQYWNWRJNXDEG-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000001856 Ethyl cellulose Substances 0.000 claims description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
- MQHWFIOJQSCFNM-UHFFFAOYSA-L Magnesium salicylate Chemical compound [Mg+2].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O MQHWFIOJQSCFNM-UHFFFAOYSA-L 0.000 claims description 2
- 229920000881 Modified starch Polymers 0.000 claims description 2
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 claims description 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 2
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 2
- WTQYWNWRJNXDEG-LEOABGAYSA-N anisodamine Chemical compound C1([C@@H](CO)C(=O)O[C@@H]2C[C@H]3[C@@H](O)C[C@@H](C2)N3C)=CC=CC=C1 WTQYWNWRJNXDEG-LEOABGAYSA-N 0.000 claims description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 2
- 229960001259 diclofenac Drugs 0.000 claims description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 2
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 claims description 2
- 229960000616 diflunisal Drugs 0.000 claims description 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 2
- 229920001249 ethyl cellulose Polymers 0.000 claims description 2
- 229960001419 fenoprofen Drugs 0.000 claims description 2
- 229960002390 flurbiprofen Drugs 0.000 claims description 2
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 claims description 2
- 229960000905 indomethacin Drugs 0.000 claims description 2
- 229960001021 lactose monohydrate Drugs 0.000 claims description 2
- 229940072082 magnesium salicylate Drugs 0.000 claims description 2
- 229960004270 nabumetone Drugs 0.000 claims description 2
- 229960002009 naproxen Drugs 0.000 claims description 2
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- 229960002702 piroxicam Drugs 0.000 claims description 2
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims description 2
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 claims description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 2
- 229960000953 salsalate Drugs 0.000 claims description 2
- 229960004025 sodium salicylate Drugs 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 claims description 2
- 229960000894 sulindac Drugs 0.000 claims description 2
- 229960001017 tolmetin Drugs 0.000 claims description 2
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 claims description 2
- FQCQGOZEWWPOKI-UHFFFAOYSA-K trisalicylate-choline Chemical compound [Mg+2].C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O FQCQGOZEWWPOKI-UHFFFAOYSA-K 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims 1
- 238000005461 lubrication Methods 0.000 claims 1
- 229960002895 phenylbutazone Drugs 0.000 claims 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 11
- 238000001514 detection method Methods 0.000 abstract description 6
- 238000003860 storage Methods 0.000 abstract description 4
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 239000008280 blood Substances 0.000 abstract description 2
- 210000004369 blood Anatomy 0.000 abstract description 2
- 238000007922 dissolution test Methods 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 239000010410 layer Substances 0.000 description 164
- 239000003826 tablet Substances 0.000 description 99
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- 239000000203 mixture Substances 0.000 description 18
- 239000007779 soft material Substances 0.000 description 16
- 238000000034 method Methods 0.000 description 13
- 238000004090 dissolution Methods 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 10
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 8
- -1 hydroxypropyl Chemical group 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 239000011248 coating agent Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 238000013268 sustained release Methods 0.000 description 6
- 239000012730 sustained-release form Substances 0.000 description 6
- 238000011049 filling Methods 0.000 description 5
- XWSCOGPKWVNQSV-UHFFFAOYSA-N 5-bromo-2,3-dichloropyridine Chemical compound ClC1=CC(Br)=CN=C1Cl XWSCOGPKWVNQSV-UHFFFAOYSA-N 0.000 description 4
- 241000220324 Pyrus Species 0.000 description 4
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 235000021017 pears Nutrition 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000007711 solidification Methods 0.000 description 4
- 230000008023 solidification Effects 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 238000009492 tablet coating Methods 0.000 description 4
- 239000002700 tablet coating Substances 0.000 description 4
- 239000004408 titanium dioxide Substances 0.000 description 4
- 229960005111 zolpidem tartrate Drugs 0.000 description 4
- HEFNNWSXXWATRW-JTQLQIEISA-N dexibuprofen Chemical compound CC(C)CC1=CC=C([C@H](C)C(O)=O)C=C1 HEFNNWSXXWATRW-JTQLQIEISA-N 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- GBBSUAFBMRNDJC-MRXNPFEDSA-N (5R)-zopiclone Chemical compound C1CN(C)CCN1C(=O)O[C@@H]1C2=NC=CN=C2C(=O)N1C1=CC=C(Cl)C=N1 GBBSUAFBMRNDJC-MRXNPFEDSA-N 0.000 description 2
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000446313 Lamella Species 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 2
- 229960000981 artemether Drugs 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- SXYIRMFQILZOAM-HVNFFKDJSA-N dihydroartemisinin methyl ether Chemical compound C1C[C@H]2[C@H](C)CC[C@H]3[C@@H](C)[C@@H](OC)O[C@H]4[C@]32OO[C@@]1(C)O4 SXYIRMFQILZOAM-HVNFFKDJSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229960003580 felodipine Drugs 0.000 description 2
- DYLGFOYVTXJFJP-MYYYXRDXSA-N lumefantrine Chemical compound C12=CC(Cl)=CC=C2C=2C(C(O)CN(CCCC)CCCC)=CC(Cl)=CC=2\C1=C/C1=CC=C(Cl)C=C1 DYLGFOYVTXJFJP-MYYYXRDXSA-N 0.000 description 2
- 229960004985 lumefantrine Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 2
- 229960002855 simvastatin Drugs 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 2
- 229960000887 spectinomycin hydrochloride Drugs 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 229960004010 zaleplon Drugs 0.000 description 2
- HUNXMJYCHXQEGX-UHFFFAOYSA-N zaleplon Chemical compound CCN(C(C)=O)C1=CC=CC(C=2N3N=CC(=C3N=CC=2)C#N)=C1 HUNXMJYCHXQEGX-UHFFFAOYSA-N 0.000 description 2
- 229960000820 zopiclone Drugs 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- OKBVVJOGVLARMR-QSWIMTSFSA-N cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 description 1
- 229960002129 cefixime Drugs 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000005489 elastic deformation Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000007948 fast release tablet Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000007896 modified release capsule Substances 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a kind of pain relieving class two-layer release-controlled tablet, including release layer and slow release layer, described slow release layer is porose, described hole is filled with immediate-release granules, described release layer and immediate-release granules are made up of with pharmaceutic adjuvant analgesic type drug, and described slow release layer is made up of analgesic type drug, slow-release material and pharmaceutic adjuvant.The present invention has the following technical effect that 1) the double-layer tablet physical stability of the present invention is better than common double synusia, is more beneficial for storage and transport.2) this two-layer release-controlled tablet is 10 ~ 30 seconds through dissolution test detection release layer disintegration, and slow release layer is zero-order release profile, greatly improves effectiveness and safety that patient takes medicine.In double-layer tablet preparation process, hole is filled with immediate-release granules.The drug release mode that rapid release combines with slow release ensure that after taking medicine, release layer fater disintegration, makes blood drug level can be rapidly achieved treatment window scope, and slow release layer continues maintaining treatment effect in being slowly released in long period of time, and effectively controls toxic and side effects.
Description
Technical field
The present invention relates to field of pharmaceutical preparations, be specifically related to a kind of pain relieving class two-layer release-controlled tablet and preparation method thereof.
Background technology
Oral solid formulation with tablet as representative is most convenient, safest administering mode, medicine clinical practice,
Always in occupation of main body and leading position in market sale and research and development.Preparation method by changing tablet is protected at present
Card medicine keeps the rock-steady structure of double-layer tablet and regulation and control release to realize the efficacy enhancing and toxicity reducing of medicine and become pharmaceuticals industry at shelf life
Most demand and practical new agent technology.Double-layer tablet be a kind of grow up on the basis of osmotic pump controlled release tablet containing bilayer
The novel two-phase medicine-releasing system of structure, its structure is different with the difference of purpose of design.Comparing with common single-layer sheet, double-layer tablet is being faced
Having many advantages in bed application, it is possible not only to combine two kinds of medicines or same medicine with different release modes reach
To preferable pharmacokinetics behavior, and can improve and have the stability of compatibility reaction medicine, moreover it is possible to give the function that tablet is special.
Double-layer tablet is generally divided into single medicine double-layer tablet and compound double-layer tablet, and single medicine double-layer tablet includes single medicine rapid release double-layer tablet, list
Medicine sustained-release double-layer tablet and single medicine speed/sustained-release double-layer tablet, wherein single medicine speed/sustained-release double-layer tablet is the double-layer tablet that a class is relatively common,
Predominantly reach optimal internal drug-time curve behavior and design, typically formed by rapid release and two kinds of granule compactings of slow release, rapid release
Layer contributes to quick relief, and slow release layer is then used for maintaining effective dose, it is achieved quick-acting and long-acting combination.
Pain not only affects quality of life, has people also can produce psychology disease owing to long pain can not get effectively treating
Sick.A lot of pain-suffered patients are owing to treating not in time, and the prevailing pain making local long-term is converted into the Regional Pain Syndrome of complexity
Or central pain, become the painful diseases of refractory.So, it should pain relieving in time.Ibuprofen ibuprofen modified release capsule in
1991 in Discussion on Chinese Listed, during one of the most safest nonsteroidal anti-inflammatory drug (NSAIDS) ibuprofen is introduced
State, its 12 hours exclusive slow release methods, make ibuprofen can not only persistently effectively pain relieving, and safe secondary effect is low, simultaneously
Use more convenient, successfully filled up China's blank in slow releasing capsule processing technology.
It is below the technology of existing double-layer tablet:
CN101073563B discloses a kind of hand-type compositions containing (S)-ibuprofen and LEVO CITRAZINE and slow
Release double-layer tablet, propose a kind of release layer containing (S)-ibuprofen and LEVO CITRAZINE and contain only the slow release of (S)-ibuprofen
The double-layer tablet of layer.Can reach and alleviate rapidly cold symptoms, the effect of long-acting performance antipyretic-antalgic.
CN102188423B discloses spectinomycin hydrochloride and felodipine sustained-release double-layer tablet and preparation method thereof, proposes
Double-layer tablet is respectively spectinomycin hydrochloride slow release layer and felodipine sustained-release layer.
CN102283829B antimalarial pharmaceutical composition and preparation method and purposes, pharmaceutical composition of the present invention will
After Artemether and benflumetol are pelletized respectively, it is prepared as double-layer tablet, it is to avoid the mixed process of Artemether and benflumetol, it is ensured that multiple
Safety in side's preparation process;Further, gained double-layer tablet disintegrate is rapid, compared with existing compound tablet, and effective ingredient dissolution
Degree significantly improves.
CN101084904B discloses cefixime sustained-release double-layer tablet, proposes a kind of release layer and that slow release layer combines is double
Synusia, the slow release layer release in vitro time is more than 12 hours.
CN102188425B double-layer tablet comprising hydrochloric acid and simvastatin and preparation method thereof, proposes at simvastatin
Release layer adds nicotinic acid, and the composition making two kinds of lamellas is close, and elastic deformation is also closer to, and will not occur in process of production point
From, the phenomenon of sliver.
In above-mentioned technology, due to double-layer tablet typically by I layer and II layer by several times compacting, therefore, medicine can be caused in transport and
The unfavorable results such as storage process Chinese medicine tablet splits.
Summary of the invention
In place of it is an object of the invention to overcome the deficiencies in the prior art, it is provided that a kind of pain relieving class two-layer release-controlled tablet and preparation thereof
Method.The drug release model that the rapid release/slow release of the present invention combines, can reach quickly alleviating pain long-time inhibition of pain, improve
Patients ' life quality.
The pain relieving class two-layer release-controlled tablet of the present invention, including release layer and slow release layer, described slow release layer is porose, described hole
In be filled with immediate-release granules, described release layer and immediate-release granules and formed by analgesic type drug and pharmaceutic adjuvant, described is slow
Release layer to be made up of analgesic type drug, slow-release material and pharmaceutic adjuvant.
A diameter of the 1 of the hole of described slow release layer~10mm.
A diameter of the 3 of the hole of described slow release layer~6mm.
Described analgesic type drug selected from aspirin, magnesium salicylate, sodium salicylate, choline magnesium trisalicylate, diflunisal,
Salsalate, ibuprofen, indomethacin, flurbiprofen, fenoprofen, naproxen, nabumetone, piroxicam, guarantor
Safe pine, diclofenac, venlofen, ketone ibuprofen, ketorolac, four clofenamic acides, sulindac, tolmetin or Anisodamine, or
One in the derivant of person's above-claimed cpd;Described slow-release material is selected from hydroxypropyl methylcellulose, ethyl cellulose, hydroxypropyl
One or more of base cellulose;Described pharmaceutic adjuvant is in filler, disintegrating agent, lubricant, binding agent, fluidizer
One or more.
Described two-layer release-controlled tablet, described filler is selected from lactose monohydrate, lactose, pregelatinized Starch and microcrystalline Cellulose
One or more;Described disintegrating agent is in cross-linking sodium carboxymethyl cellulose, carboxymethyl starch sodium and polyvinylpolypyrrolidone
One or more;Described lubricant selected from stearic acid, magnesium stearate and talcous one or more;Described binding agent choosing
From one or more of polyvidone, hydroxypropyl cellulose and hydroxypropyl methylcellulose;Described fluidizer is silicon dioxide.
Described two-layer release-controlled tablet, in described slow release layer, includes following components according to percentage by weight:
In described release layer and immediate-release granules, include following components according to percentage by weight:
Described two-layer release-controlled tablet also includes coatings, and described coatings includes following components according to percentage by weight:
The preparation method of the pain relieving class two-layer release-controlled tablet of the present invention, it is characterised in that comprise the following steps:
1) analgesic type drug is mixed and made into slow-releasing granules with slow-release material and pharmaceutic adjuvant;By analgesic type drug with medicinal
Adjuvant is mixed and made into immediate-release granules;
2) slow-releasing granules is pressed into porose slow release layer, then slow release layer is reentered in the punch die of tablet machine, filling
Immediate-release granules, carries out second time and suppresses, and forms the double-layer tablet being made up of release layer and slow release layer, wherein fills in the hole of slow release layer
There is immediate-release granules.
The preparation method of described pain relieving class two-layer release-controlled tablet, also includes the step of coating.
Additionally include the step of coating.
The present invention has the following technical effect that
1) the double-layer tablet physical stability that prepared by the present invention is better than common double synusia, is more beneficial for storage and transport.Due to
The slow release layer of two-layer release-controlled tablet is porose, and immediate-release granules in natural ostium, makes double-layer tablet be tightly combined in pressing process,
Storing and transportation is being not readily separated.
2) this two-layer release-controlled tablet is 10~30 seconds through dissolution test detection release layer disintegration, and slow release layer is Zero order release
Pattern, greatly improves effectiveness and safety that patient takes medicine.In double-layer tablet preparation process, hole is filled with rapid release
Grain.The drug release mode that rapid release combines with slow release ensure that after taking medicine, release layer fater disintegration, makes blood drug level quickly to reach
To treatment window scope, slow release layer continues maintaining treatment effect in being slowly released in long period of time, and it is secondary effectively to control poison
Effect.
Accompanying drawing explanation
Fig. 1 is the structure chart of single hole double-layer tablet prepared by the present invention;
Fig. 2 is the structure chart of diplopore double-layer tablet prepared by the present invention;
Fig. 3 is the structure chart of three hole double-layer tablet prepared by the present invention;
Fig. 4 is the impact on dissolution of the slow release layer different pore size;
Fig. 5 is embodiment 1 two-layer release-controlled tablet In-vitro release curves;
Fig. 6 is embodiment 2 two-layer release-controlled tablet sheet In-vitro release curves;
Fig. 7 is embodiment 3 two-layer release-controlled tablet sheet In-vitro release curves;
Fig. 8 is the embodiment 4 external stripping curve of two-layer release-controlled tablet sheet.
Wherein, 1 is slow release layer;2 is release layer;3 is hole.
Detailed description of the invention.
The prescription of the two-layer release-controlled tablet of embodiment 1-5 such as following table:
The prescription of the two-layer release-controlled tablet of each embodiment (1000, g)
Above-mentioned double-layer tablet can use coating, and coatings is containing following component:
Embodiment 1
The prescription of the two-layer release-controlled tablet of the present embodiment is as shown in table 1.Its preparation method is as follows:
1, slow-releasing granules is prepared:
(1) Zolpidemtar Trate crossing 60 mesh sieves and hydroxypropyl methylcellulose K100LV, K4M, the breast of recipe quantity are weighed
Sugar is sufficiently mixed, and adds silicon dioxide and the magnesium stearate of recipe quantity 1/2nd afterwards.The material mixed is transferred to wet
In method granulator;
(2) compound concentration be 70% ethanol solution the mixture in step 1 is carried out soft material processed;
(3) soft material made is carried out granulate with 24 mesh sieves;
(4) it is dried and sieves granule
(5) obtain slow-releasing granules, be used for forming slow release layer.
2, immediate-release granules is prepared:
(1) by the Zolpidemtar Trate of recipe quantity, lactose, microcrystalline Cellulose, polyvidone mixed 60 mesh sieves, added prescription
The silicon dioxide of amount half and magnesium stearate, mix homogeneously in batch mixer;
(2) compound concentration be 80% ethanol solution the mixture in step 1 is carried out soft material processed;
(3) soft material made is carried out granulate with 24 mesh sieves;
(4) it is dried and sieves powder particles;
(5) add cross-linking sodium carboxymethyl cellulose according to outer addition to mix homogeneously with dry granule;
(6) immediate-release granules is obtained, for forming release layer and for filling the hole of slow release layer.
3, two-layer release-controlled tablet is prepared:
(1) slow release layer granule is added remaining silicon dioxide and magnesium stearate is pressed into middle porose slow releasing tablet, aperture
It is respectively 3mm, 4mm, 6mm;The most also suppress the slow releasing tablet not having hole;
(2) slow releasing tablet is reentered in the punch die of tablet machine, loads release layer granule, rush in row second time pressure by scrobicula
System, forms double-layer tablet;
(3) the hydroxypropyl methyl cellulose E 5 of recipe quantity being dispersed in concentration is in 80% ethanol, the poly-mountain of swelling rear addition
Pears alcohol ester 80, stirring and dissolving is complete, adds titanium dioxide and Pulvis Talci, stirs, as coating solution after filtration;
(4) by double-layer tablet coating, every weightening finish 5%, then dry solidification are made.
In order to investigate the impact on dissolution of the slow release layer aperture, slow release layer is first suppressed into the most with holes, band 3mm by the present embodiment
Hole, band 4mm hole, the slow releasing tablet in band 6mm aperture, carry out dissolution experiment, and slow release layer aperture is the biggest, and dissolution rate is the fastest.Result is shown in
Fig. 4.
The double-layer tablet prepared is carried out dissolution experiment, the effect of slow release after investigation tablet elder generation rapid release, 0.5h samples detection,
Release layer dissolution completely, result is shown in Fig. 5.
Embodiment 2
The prescription of the two-layer release-controlled tablet of the present embodiment is as shown in table 1.Its preparation method is as follows:
1, slow-releasing granules is prepared:
(1) Zolpidemtar Trate crossing 60 mesh sieves and hydroxypropyl methylcellulose K100LV, K4M, the breast of recipe quantity are weighed
Sugar is sufficiently mixed, and adds silicon dioxide and the magnesium stearate of recipe quantity 1/2nd afterwards.The material mixed is transferred to wet
In method granulator;
(2) compound concentration be 75% ethanol solution the mixture in step 1 is carried out soft material processed;
(3) soft material made is carried out granulate with 24 mesh sieves;
(4) it is dried and sieves granule
(5) obtain slow-releasing granules, be used for forming slow release layer.
2, immediate-release granules is prepared:
(1) by the Zolpidemtar Trate of recipe quantity, lactose, microcrystalline Cellulose and hydroxypropyl cellulose-HF, carboxymethyl cellulose
Element sodium mixed 60 mesh sieves, added silicon dioxide and magnesium stearate, the mix homogeneously in batch mixer of recipe quantity half;
(2) compound concentration be 90% ethanol solution the mixture in step 1 is carried out soft material processed;
(3) soft material made is carried out granulate with 24 mesh sieves;
(4) it is dried and sieves powder particles
(5) immediate-release granules is obtained, for forming release layer and for filling the hole of slow release layer.
3, two-layer release-controlled tablet is prepared:
(1) slow release layer granule is added remaining silicon dioxide and magnesium stearate is pressed into middle porose slow releasing tablet, aperture
It is respectively 4mm, 6mm;
(2) slow releasing tablet is reentered in the punch die of tablet machine, loads release layer granule, rush in row second time pressure by scrobicula
System, forms double-layer tablet;
(3) the hydroxypropyl methyl cellulose E 5 of recipe quantity being dispersed in concentration is in 80% ethanol, the poly-mountain of swelling rear addition
Pears alcohol ester 80, stirring and dissolving is complete, adds titanium dioxide and Pulvis Talci, stirs, as coating solution after filtration;
(4) by double-layer tablet coating, every weightening finish 5%, then dry solidification are made.
The effect of slow release after investigation double-layer tablet release layer disintegration rate, and double-layer tablet elder generation rapid release, 0.25h samples detection, speed
Releasing layer dissolution more than 85%, result is shown in Fig. 6.
Embodiment 3
The prescription of the two-layer release-controlled tablet of the present embodiment is as shown in table 1.Its preparation method is as follows:
1, slow-releasing granules is prepared:
(1) weighing the zopiclone crossing 60 mesh sieves and hydroxypropyl methylcellulose K100LV, the K4M of recipe quantity, lactose fills
Divide mixing, add silicon dioxide and the magnesium stearate of recipe quantity 1/2nd afterwards.The material mixed is transferred to wet method system
In grain machine;
(2) compound concentration be 80% ethanol solution the mixture in step 1 is carried out soft material processed;
(3) soft material made is carried out granulate with 24 mesh sieves;
(4) it is dried and sieves granule
(5) obtain slow-releasing granules, be used for forming slow release layer.
2, immediate-release granules is prepared:
(1) by the zopiclone of recipe quantity, lactose, microcrystalline Cellulose and hydroxypropyl cellulose-HF, sodium carboxymethyl cellulose
Mix 60 mesh sieves, add silicon dioxide and magnesium stearate, the mix homogeneously in batch mixer of recipe quantity half;
(2) compound concentration be 90% ethanol solution the mixture in step 1 is carried out soft material processed;
(3) soft material made is carried out granulate with 24 mesh sieves;
(4) it is dried and sieves powder particles
(5) immediate-release granules is obtained, for forming release layer and for filling the hole of slow release layer.
3, two-layer release-controlled tablet is prepared:
(1) slow release layer granule is added remaining silicon dioxide and magnesium stearate is pressed into middle porose slow releasing tablet, aperture
It is respectively 4mm, 6mm;
(2) slow releasing tablet is reentered in the punch die of tablet machine, loads release layer granule, rush in row second time pressure by scrobicula
System, forms double-layer tablet;
(3) the hydroxypropyl methyl cellulose E 5 of recipe quantity being dispersed in concentration is in 80% ethanol, the poly-mountain of swelling rear addition
Pears alcohol ester 80, stirring and dissolving is complete, adds titanium dioxide and Pulvis Talci, stirs, as coating solution after filtration;
(4) by double-layer tablet coating, every weightening finish 5%, then dry solidification are made.
The double-layer tablet prepared is carried out dissolution experiment, the effect of slow release after investigation tablet elder generation rapid release, 0.5h samples detection,
Release layer dissolution completely, result is shown in Fig. 7.
Embodiment 4
The prescription of the two-layer release-controlled tablet of the present embodiment is as shown in table 1.Its preparation method is as follows:
1, slow-releasing granules is prepared:
(1) weighing the Zaleplon crossing 60 mesh sieves and hydroxypropyl methylcellulose K100LV, the K4M of recipe quantity, lactose fills
Divide mixing, add silicon dioxide and the magnesium stearate of recipe quantity 1/2nd afterwards.The material mixed is transferred to wet method system
In grain machine;
(2) compound concentration be 80% ethanol solution the mixture in step 1 is carried out soft material processed;
(3) soft material made is carried out granulate with 24 mesh sieves;
(4) it is dried and sieves granule
(5) obtain slow-releasing granules, be used for forming slow release layer.
2, immediate-release granules is prepared:
(1) by the Zaleplon of recipe quantity, lactose, microcrystalline Cellulose and hydroxypropyl cellulose-HF, sodium carboxymethyl cellulose
Mix 60 mesh sieves, add silicon dioxide and magnesium stearate, the mix homogeneously in batch mixer of recipe quantity half;
(2) compound concentration be 90% ethanol solution the mixture in step 1 is carried out soft material processed;
(3) soft material made is carried out granulate with 24 mesh sieves;
(4) it is dried and sieves powder particles
(5) immediate-release granules is obtained, for forming release layer and for filling the hole of slow release layer.
3, two-layer release-controlled tablet is prepared:
(1) slow release layer granule is added remaining silicon dioxide and magnesium stearate is pressed into middle porose slow releasing tablet, aperture
It is respectively 4mm, 6mm;
(2) slow releasing tablet is reentered in the punch die of tablet machine, loads release layer granule, rush in row second time pressure by scrobicula
System, forms double-layer tablet;
(3) the hydroxypropyl methyl cellulose E 5 of recipe quantity being dispersed in concentration is in 80% ethanol, the poly-mountain of swelling rear addition
Pears alcohol ester 80, stirring and dissolving is complete, adds titanium dioxide and Pulvis Talci, stirs, as coating solution after filtration;
(4) by double-layer tablet coating, every weightening finish 5%, then dry solidification are made.
Prepare monolayer fast-release tablet and double-layer tablet carries out dissolution experiment, investigate tablet release layer disintegration rate, and double-layer tablet is first
The effect of slow release after rapid release, 0.5h samples detection, and release layer dissolution is more than 90%, and result is shown in Fig. 8.
Embodiment 5
The prescription of the two-layer release-controlled tablet of the present embodiment is as shown in table 1.Its preparation method is with embodiment 3.
The experiment of embodiment 6 friability and stability experiment
According to the method in embodiment 1, being prepared for slow release layer does not has hole (to be i.e. simply made up of one layer of rapid release of one layer of slow release
Double-layer tablet), slow release layer have a 3mm hole, slow release layer to have a 4mm hole and slow release layer to have the double-layer tablet each 100 in a 6mm hole
Sheet, carries out friability Experimental comparison's research, result such as table 2 in friability detector respectively:
Table 2
From table 2 it can be seen that in the case of supplementary material composition and proportioning are completely the same, 100 double-layer tablet not having hole
The sheet number of layering is occurred to have 8 in upset collision.Separately take with 100 porose, double-layer tablet 6mm aperture, 100,4mm aperture,
100,3mm aperture carries out same experimentation, and result shows the relatively cracky that aperture is big, but all without the phenomenon of lamella separation.
According to the method in embodiment 4, be prepared for slow release layer do not have hole, slow release layer have 3mm hole, slow release layer have 4mm hole and
Slow release layer has each 20 of the double-layer tablet in 6mm hole, is positioned in stability test case, and humidity set is RH95%, and temperature is set to 25
DEG C, observe after placing 24h, result such as table 3 below:
Table 3
Slow release layer does not has what 20 middle levels in hole separated to have 18, and porose not have the appearance being layered.
Containing super-disintegrant in this prescription release layer, the hygroscopicity of disintegrating agent is relatively strong, when ambient humidity is bigger, and rapid release
Layer is bigger than slow release layer degrees of expansion, and the double-layer tablet levels not having hole is easily separated.Rapid release after slow release layer band is porose, in hole
Grain moisture expantion, release layer engages tightr with slow release layer.Historical facts or anecdotes test during with porose double-layer tablet all without segregation phenomenon.
According to the method for embodiment 3, suppressed respectively slow release layer do not have hole, one hole of slow release layer, two holes of slow release layer and
The double-layer tablet in three holes of slow release layer, owing to containing only active component and excipient in release layer, does not contains binding agent, respectively takes 20
Sheet, carries out friability Experimental comparison's research, result such as table 4 in friability detector respectively:
Table 4
It can be seen from the results above that double-layer tablet physical stability prepared by the present invention is better than common double synusia, more favorably
In storage and transport.
Claims (6)
1. a pain relieving class two-layer release-controlled tablet, including release layer and slow release layer, it is characterised in that described slow release layer is porose, institute
The hole stated is filled with immediate-release granules, described release layer and immediate-release granules formed with pharmaceutic adjuvant by analgesic type drug, institute
The slow release layer stated is made up of analgesic type drug, slow-release material and pharmaceutic adjuvant, a diameter of the 3 of the hole of described slow release layer~6mm,
The number in hole is 1-3;
The described two-layer release-controlled piece preparation method of pain relieving class is as follows:
1) analgesic type drug is mixed and made into slow-releasing granules with slow-release material and pharmaceutic adjuvant;By analgesic type drug and pharmaceutic adjuvant
It is mixed and made into immediate-release granules;
2) slow-releasing granules is pressed into porose slow release layer, then slow release layer is reentered in the punch die of tablet machine, load rapid release
Granule, carries out second time and suppresses, form the double-layer tablet being made up of release layer and slow release layer, be wherein filled with speed in the hole of slow release layer
Release granule.
Two-layer release-controlled tablet the most according to claim 1, it is characterised in that described analgesic type drug selected from aspirin,
Magnesium salicylate, sodium salicylate, choline magnesium trisalicylate, diflunisal, salsalate, ibuprofen, indomethacin, flurbiprofen,
Fenoprofen, naproxen, nabumetone, piroxicam, Phenylbutazone, diclofenac, venlofen, ketone ibuprofen, ketone are coughed up
Any one in acid, four clofenamic acides, sulindac, tolmetin or Anisodamine;Described slow-release material is selected from hydroxypropyl
Cellulose, ethyl cellulose, hydroxypropyl cellulose one or more;Described pharmaceutic adjuvant is selected from filler, disintegrating agent, profit
One or more in lubrication prescription, binding agent, fluidizer.
Two-layer release-controlled tablet the most according to claim 2, it is characterised in that described filler selected from lactose monohydrate, lactose,
One or more of pregelatinized Starch and microcrystalline Cellulose;Described disintegrating agent is selected from cross-linking sodium carboxymethyl cellulose, carboxymethyl
One or more in Starch Sodium and polyvinylpolypyrrolidone;Described lubricant is selected from stearic acid, magnesium stearate and talcous
Plant or several;Described binding agent is selected from one or more of polyvidone, hydroxypropyl cellulose and hydroxypropyl methylcellulose;Described
Fluidizer be silicon dioxide.
Two-layer release-controlled tablet the most according to claim 1, it is characterised in that
In described slow release layer, include following components according to percentage by weight:
In described release layer and immediate-release granules, include following components according to percentage by weight:
Two-layer release-controlled tablet the most according to claim 1, it is characterised in that also include coatings, described coatings according to
Percentage by weight includes following components:
6. according to the pain relieving class two-layer release-controlled tablet described in claim 1, it is characterised in that described preparation method also includes bag
The step of clothing.
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310716482.6A CN103655505B (en) | 2013-12-23 | 2013-12-23 | A kind of pain relieving class two-layer release-controlled tablet and preparation method thereof |
DK14874251.3T DK3087980T3 (en) | 2013-12-23 | 2014-12-19 | DOUBLE LAYER TABLE AND METHOD OF PRODUCING THEREOF |
JP2016543032A JP6296371B2 (en) | 2013-12-23 | 2014-12-19 | Preparation method of bilayer tablet |
PCT/CN2014/094367 WO2015096668A1 (en) | 2013-12-23 | 2014-12-19 | Double-layer tablet and preparation method thereof |
US15/107,892 US10137092B2 (en) | 2013-12-23 | 2014-12-19 | Double-layer tablet and preparation method thereof |
ES14874251T ES2712129T3 (en) | 2013-12-23 | 2014-12-19 | Double-layer tablet and method of preparation |
EP14874251.3A EP3087980B1 (en) | 2013-12-23 | 2014-12-19 | Double-layer tablet and preparation method thereof |
US16/178,547 US10925836B2 (en) | 2013-12-23 | 2018-11-01 | Double-layer tablet and painkiller tablet with same structure |
US16/178,543 US10940114B2 (en) | 2013-12-23 | 2018-11-01 | Hypnotics tablet with double-layer structure |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310716482.6A CN103655505B (en) | 2013-12-23 | 2013-12-23 | A kind of pain relieving class two-layer release-controlled tablet and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103655505A CN103655505A (en) | 2014-03-26 |
CN103655505B true CN103655505B (en) | 2016-10-26 |
Family
ID=50295070
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310716482.6A Active CN103655505B (en) | 2013-12-23 | 2013-12-23 | A kind of pain relieving class two-layer release-controlled tablet and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103655505B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10137092B2 (en) | 2013-12-23 | 2018-11-27 | Xiaoguang WEN | Double-layer tablet and preparation method thereof |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103948556A (en) * | 2014-04-08 | 2014-07-30 | 闻晓光 | Novel controlled release tablet |
CN109316457B (en) * | 2018-11-26 | 2021-07-13 | 正大制药(青岛)有限公司 | Cyclobenzaprine hydrochloride sustained release preparation and preparation method thereof |
CN110037994B (en) * | 2019-05-24 | 2022-04-12 | 中国药科大学 | Ibuprofen quick-release and slow-release double-layer tablet and preparation method thereof |
CN114177155B (en) * | 2020-09-08 | 2023-10-03 | 越洋医药开发(广州)有限公司 | Ibuprofen controlled release tablet and preparation method thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102085196A (en) * | 2009-12-08 | 2011-06-08 | 北京科信必成医药科技发展有限公司 | Nefopam hydrochloride bilayer slow-release tablet and preparation method thereof |
WO2012118180A1 (en) * | 2011-03-03 | 2012-09-07 | 武田薬品工業株式会社 | Laminated tablet and manufacturing method therefor |
-
2013
- 2013-12-23 CN CN201310716482.6A patent/CN103655505B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102085196A (en) * | 2009-12-08 | 2011-06-08 | 北京科信必成医药科技发展有限公司 | Nefopam hydrochloride bilayer slow-release tablet and preparation method thereof |
WO2012118180A1 (en) * | 2011-03-03 | 2012-09-07 | 武田薬品工業株式会社 | Laminated tablet and manufacturing method therefor |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10137092B2 (en) | 2013-12-23 | 2018-11-27 | Xiaoguang WEN | Double-layer tablet and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
CN103655505A (en) | 2014-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103655505B (en) | A kind of pain relieving class two-layer release-controlled tablet and preparation method thereof | |
RU2616516C2 (en) | Pharmaceutical composition containing olmesartan medoxomil and rosuvastatin or its salt | |
CN101257894A (en) | Sustained release pharmaceutical compositions for highly water soluble drugs | |
US11883399B2 (en) | Bromocriptine formulations | |
WO2011071139A1 (en) | Dry-coated orally disintegrating tablet | |
CN113018273A (en) | Solid preparation and preparation method and application thereof | |
EP3130334B1 (en) | Controlled-release solid preparation with partial coating | |
CN115518066A (en) | Pharmaceutical composition for treating anticoagulation and application | |
CN103690505B (en) | A kind of sleeping class two-layer release-controlled tablet and preparation method thereof | |
SK2902003A3 (en) | Pharmaceutical compositions comprising 5-methyl-2(2'-chloro-6'- fluoroanilino) phenylacetic acid or a pharmaceutically acceptable salt thereof | |
WO2015096668A1 (en) | Double-layer tablet and preparation method thereof | |
JPWO2017047586A1 (en) | tablet | |
CN103690503B (en) | A kind of preparation method of double-layer tablet | |
WO2012139736A1 (en) | Pharmaceutical composition comprising bosentan | |
CN106580898B (en) | A kind of erigeron breviscapus dispersion tablet and preparation method | |
CA2735203C (en) | A method for the production of bioadhesive compact matrices that can be used either as such or for the prolonged release of active substances, and compact matrices thus obtained | |
AU2020301401B2 (en) | Novel ibuprofen and acetaminophen composition | |
CN103222966A (en) | Solid pharmaceutical composition containing Fingolimod hydrochloride and preparation method thereof | |
CN116869951A (en) | Modified release formulation of naproxen sodium | |
Naik et al. | Development of single unit floating-pulsatile site specific drug delivery system for chronotherapeutic release of aceclofenac | |
CN115919867B (en) | Aidenafil citrate oral sustained-release preparation and preparation method and application thereof | |
US20180344648A1 (en) | Clobazam tablet formulation and process for its preparation | |
RU2611339C2 (en) | Pharmaceutical compositions with prolonged release for treating cerebrovascular disorders | |
WO2012045863A1 (en) | Pharmaceutical compositions comprising glimepiride and polyethylene glycol castor oil | |
Patel et al. | Pulsatile release of ketoprofen from compression coated tablets using Eudragit (r) polymers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20180827 Address after: 510000 self compiled A015 of A Building 5, No. 2, No. 2, No. Patentee after: Yueyang medicine (Guangzhou) Development Co., Ltd. Address before: 225300, 1 new drug development base, No. 1209, Yao Cheng Road, Taizhou, Jiangsu, 2 phase D building, room 1209. Patentee before: Wen Xiaoguang |